Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease - Trial NCT06422208
Access comprehensive clinical trial information for NCT06422208 through Pure Global AI's free database. This Phase 1 trial is sponsored by Penelope J. Hallett, Ph.D. and is currently Not yet recruiting. The study focuses on Parkinson Disease. Target enrollment is 6 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Penelope J. Hallett, Ph.D.
Mclean Hospital
Timeline & Enrollment
Phase 1
Jun 01, 2024
Aug 01, 2027
Primary Outcome
Safety: number and severity of adverse events and serious adverse events
Summary
This research study is evaluating an investigational cell product called autologous induced
 pluripotent stem cell-derived dopamine neurons. This research study is a single-center Phase
 1 clinical trial, which will test the safety of injecting the investigational cell product
 into the brain of subjects with Parkinson's disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06422208
Non-Device Trial